367 related articles for article (PubMed ID: 34083230)
1. Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study.
Davids MS; Roberts AW; Kenkre VP; Wierda WG; Kumar A; Kipps TJ; Boyer M; Salem AH; Pesko JC; Arzt JA; Mantas M; Kim SY; Seymour JF
Clin Cancer Res; 2021 Sep; 27(17):4690-4695. PubMed ID: 34083230
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
Kirschbaum M; Frankel P; Popplewell L; Zain J; Delioukina M; Pullarkat V; Matsuoka D; Pulone B; Rotter AJ; Espinoza-Delgado I; Nademanee A; Forman SJ; Gandara D; Newman E
J Clin Oncol; 2011 Mar; 29(9):1198-203. PubMed ID: 21300924
[TBL] [Abstract][Full Text] [Related]
3. An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
Andorsky DJ; Kolibaba KS; Assouline S; Forero-Torres A; Jones V; Klein LM; Patel-Donnelly D; Smith M; Ye W; Shi W; Yasenchak CA; Sharman JP
Br J Haematol; 2019 Jan; 184(2):215-222. PubMed ID: 30183069
[TBL] [Abstract][Full Text] [Related]
4. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
Davids MS; Roberts AW; Seymour JF; Pagel JM; Kahl BS; Wierda WG; Puvvada S; Kipps TJ; Anderson MA; Salem AH; Dunbar M; Zhu M; Peale F; Ross JA; Gressick L; Desai M; Kim SY; Verdugo M; Humerickhouse RA; Gordon GB; Gerecitano JF
J Clin Oncol; 2017 Mar; 35(8):826-833. PubMed ID: 28095146
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use.
Hughes ME; Landsburg DJ; Rubin DJ; Schuster SJ; Svoboda J; Gerson JN; Namoglu E; Nasta SD
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):791-798. PubMed ID: 31648953
[TBL] [Abstract][Full Text] [Related]
6. Venetoclax in Previously Treated Waldenström Macroglobulinemia.
Castillo JJ; Allan JN; Siddiqi T; Advani RH; Meid K; Leventoff C; White TP; Flynn CA; Sarosiek S; Branagan AR; Demos MG; Guerrera ML; Kofides A; Liu X; Munshi M; Tsakmaklis N; Xu L; Yang G; Patterson CJ; Hunter ZR; Davids MS; Furman RR; Treon SP
J Clin Oncol; 2022 Jan; 40(1):63-71. PubMed ID: 34793256
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma.
Goto H; Ito S; Kizaki M; Yamaguchi M; Fukuhara N; Kato K; Saito T; Terui Y; Okubo S; Soshin T; Zeng J; Honda H; Badawi M; Ross JA; Izutsu K
Int J Clin Oncol; 2024 Feb; 29(2):232-240. PubMed ID: 38157190
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.
Chen R; Frankel P; Popplewell L; Siddiqi T; Ruel N; Rotter A; Thomas SH; Mott M; Nathwani N; Htut M; Nademanee A; Forman SJ; Kirschbaum M
Haematologica; 2015 Mar; 100(3):357-62. PubMed ID: 25596263
[TBL] [Abstract][Full Text] [Related]
9. A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Ogura M; Ando K; Suzuki T; Ishizawa K; Oh SY; Itoh K; Yamamoto K; Au WY; Tien HF; Matsuno Y; Terauchi T; Yamamoto K; Mori M; Tanaka Y; Shimamoto T; Tobinai K; Kim WS
Br J Haematol; 2014 Jun; 165(6):768-76. PubMed ID: 24617454
[TBL] [Abstract][Full Text] [Related]
10. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.
de Vos S; Swinnen LJ; Wang D; Reid E; Fowler N; Cordero J; Dunbar M; Enschede SH; Nolan C; Petrich AM; Ross JA; Salem AH; Verdugo M; Agarwal S; Zhou L; Kozloff M; Nastoupil LJ; Flowers CR
Ann Oncol; 2018 Sep; 29(9):1932-1938. PubMed ID: 30060083
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study.
Zinzani PL; Vose JM; Czuczman MS; Reeder CB; Haioun C; Polikoff J; Tilly H; Zhang L; Prandi K; Li J; Witzig TE
Ann Oncol; 2013 Nov; 24(11):2892-7. PubMed ID: 24030098
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.
Kumar S; Kaufman JL; Gasparetto C; Mikhael J; Vij R; Pegourie B; Benboubker L; Facon T; Amiot M; Moreau P; Punnoose EA; Alzate S; Dunbar M; Xu T; Agarwal SK; Enschede SH; Leverson JD; Ross JA; Maciag PC; Verdugo M; Touzeau C
Blood; 2017 Nov; 130(22):2401-2409. PubMed ID: 29018077
[TBL] [Abstract][Full Text] [Related]
13. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.
Witzig TE; Vose JM; Zinzani PL; Reeder CB; Buckstein R; Polikoff JA; Bouabdallah R; Haioun C; Tilly H; Guo P; Pietronigro D; Ervin-Haynes AL; Czuczman MS
Ann Oncol; 2011 Jul; 22(7):1622-1627. PubMed ID: 21228334
[TBL] [Abstract][Full Text] [Related]
14. A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia.
Panayiotidis P; Tumyan G; Thieblemont C; Ptushkin VV; Marin-Niebla A; García-Sanz R; Le Gouill S; Stathis A; Bottos A; Hamidi H; Katz P; Perretti T; Willis JC; Buske C
Leuk Lymphoma; 2022 May; 63(5):1058-1069. PubMed ID: 35045765
[TBL] [Abstract][Full Text] [Related]
15. Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma.
Witzig TE; Luigi Zinzani P; Habermann TM; Tuscano JM; Drach J; Ramchandren R; Kalayoglu Besisik S; Takeshita K; Casadebaig Bravo ML; Zhang L; Fu T; Goy A
Am J Hematol; 2017 Oct; 92(10):E575-E583. PubMed ID: 28699256
[TBL] [Abstract][Full Text] [Related]
16. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
[TBL] [Abstract][Full Text] [Related]
17. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
Wang M; Ramchandren R; Chen R; Karlin L; Chong G; Jurczak W; Wu KL; Bishton M; Collins GP; Eliadis P; Peyrade F; Lee Y; Eckert K; Neuenburg JK; Tam CS
J Hematol Oncol; 2021 Oct; 14(1):179. PubMed ID: 34717692
[TBL] [Abstract][Full Text] [Related]
18. A comprehensive retrospective cohort study of the journey of B-cell lymphoma in Taiwan.
Pei SN; Wang MC; Ma MC; Kuo CY; Liao CK; Qiu H; Rothwell LA; Liu Y
Sci Rep; 2021 May; 11(1):10069. PubMed ID: 33980914
[TBL] [Abstract][Full Text] [Related]
19. Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma.
Parikh A; Gopalakrishnan S; Freise KJ; Verdugo ME; Menon RM; Mensing S; Salem AH
Leuk Lymphoma; 2018 Apr; 59(4):871-879. PubMed ID: 28797193
[TBL] [Abstract][Full Text] [Related]
20. Real World Long-term Follow-up Experience with Yttrium-90 ibritumomab tiuxetan in Previously Untreated Patients with Low-Grade Follicular Lymphoma and Marginal Zone Lymphoma.
Alhaj Moustafa M; Peterson J; Hoppe BS; Jiang J; Wiseman GA; Witzig TE; Tun HW
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):618-625. PubMed ID: 35400611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
